Sydney, Oct 28, 2005 AEST (ABN Newswire) - Clinical Cell Culture Ltd (ASX: CCE) announced that the first CellSpray R patient has been treated in Europe.
CellSpray R is intended for use in patients with between 30-90% injuries to the body. CellSpray R was launched in September at the European Burns Association meeting in Portugal, which was attended by leading surgeons from throughout Europe.
Surgeons and medical practitioners in 20 hospitals in German speaking countries have now been trained in using the CellSpray R technology. The first CellSpray R treatment in Halle, Germany follows the first CellSpray R XP treatment in July which has been followed by further patient treatments. CellSpray R XP is intended for use in patients with injuries of 10-30% of the body surface.
C3's Managing Director Troels Jordansen said the treatment of the first patient using CellSpray R highlighted the significance of the product within the medical community as a unique and applied autologous cell therapy product to treat burns and other injuries. "The CellSpray R technology has already captured the interest of several burn surgeons.
The ease of application and speed of availability are key drivers of interest in the product, as are the improved clinical outcomes", he said.
CellSpray R is available for sale in those European countries where it has regulatory approval - Austria, Denmark, Germany, The Netherlands and UK. In addition to these countries, CellSpray R XP is also available for sale in Switzerland and Italy. C3 has a rolling program of regulatory approval applications in Europe and in targeted markets around the world.
Contact
Andrew Cannon or Troels Jordansen
Clinical Cell Culture
Tel: +44 (0)1223 341 150
Email: investor@clinicalcellculture.com
| ||
|
